Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

05/02/2026 06:32

Feb 5 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2025        Dec 31, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              210.76              222.77           294.00    
                   (-5.4 pct)          (+0.0 pct)       (-2.0 pct)  
  Operating           28.22               35.20            44.00    
                   (-19.8 pct)         (-2.7 pct)       (-6.1 pct)  
  Pretax
  Net                 21.82               27.47            34.00    
                   (-20.6 pct)         (+3.2 pct)       (-6.2 pct)  
  EPS Basic         66.16 yen           78.21 yen       102.66 yen  
  EPS Diluted       66.05 yen           77.98 yen                   
  Ann Div                               36.00 yen        38.00 yen  
  -Q2 Div           19.00 yen           17.00 yen                   
  -Q4 Div                               19.00 yen        19.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T